Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scinopharm TaiwanTPE:1789 78 EV-to-EBIT is 623.38 as of Aug. 22, 2026, which is 1338% above its 10-year median of 43.35. GuruFocus rates TPE:1789 with a GF Score™ of 78/100 and a GF Value™ of NT$20.20 (Fairly Valued). The stock has 8 warning signs investors should review. Among 690 Drug Manufacturers companies, Scinopharm Taiwan ranks worse than 99.28% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Scinopharm Taiwan's Enterprise Value for the quarter that ended in Jun. 2026 was NT$13,703 Mil.
Scinopharm Taiwan's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scinopharm Taiwan EV-to-EBIT Related Terms
Scinopharm Taiwan EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Scinopharm Taiwan's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scinopharm Taiwan EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Scinopharm Taiwan's EV-to-EBIT falls into.
Scinopharm Taiwan's current Enterprise Value is NT$12,754 Mil.
Scinopharm Taiwan's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scinopharm Taiwan (TPE:1789) has a EV-to-EBIT of 623.38 as of Aug. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Scinopharm Taiwan and its competitors. This is 1338% above median its historical median of 43.35. Over the past decade, Scinopharm Taiwan's EV-to-EBIT has ranged from 27.76 to 776.81. According to the industry distribution chart, Scinopharm Taiwan ranks #685 out of 690 companies in the Drug Manufacturers industry, placing it in the top 99.3%.
Is Scinopharm Taiwan's EV-to-EBIT too high?
Scinopharm Taiwan's current EV-to-EBIT of 623.38 is 1338% above median its 10-year median of 43.35. Over the past 10 years, this metric has ranged from a low of 27.76 to a high of 776.81. The Drug Manufacturers industry median EV-to-EBIT is 15.12. Scinopharm Taiwan's value of 623.38 is 4024.2% above this industry median. Based on the distribution chart, Scinopharm Taiwan ranks #685 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Scinopharm Taiwan has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Scinopharm Taiwan ranks #685 out of 690 companies for EV-to-EBIT. This places Scinopharm Taiwan in the lower half of its industry. The industry median EV-to-EBIT is 15.12. Scinopharm Taiwan's value of 623.38 is 4024.2% above this benchmark. Historically, Scinopharm Taiwan's own EV-to-EBIT has ranged from 27.76 to 776.81 over the past decade. While the company's 10-year median is 43.35 vs. the industry median of 15.12, Scinopharm Taiwan has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.12, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scinopharm Taiwan's current EV-to-EBIT of 623.38 is 4024.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Scinopharm Taiwan and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scinopharm Taiwan's current EV-to-EBIT is 623.38, which is 1338% above median its own 10-year median of 43.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Fairly Valued. The stock's GF Value™ is NT$20.20, compared to a current price of NT$19.45 — trading 3.7% below its estimated fair value. The current EV-to-EBIT is 623.38, which is 1338% above median its 10-year median of 43.35 and 4024.2% above the Drug Manufacturers industry median of 15.12. Scinopharm Taiwan's overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current EV-to-EBIT is 623.38 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?
Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued.
The current stock price of NT$19.45 is trading 3.7% below its estimated GF Value™ of NT$20.20.
GuruFocus considers Scinopharm Taiwan to be Fairly Valued.
Key valuation signals for TPE:1789:
EV-to-EBIT: 623.38 (1338% above median its 10-year median of 43.35)
GF Value™: NT$20.20 vs. price of NT$19.45 (3.7% below fair value)
Industry Position: 4024.2% above the Drug Manufacturers median (#685 of 690)
No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
78GF Score
Get the complete analysis for TPE:1789
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1789 has been successfully added to your 
